A Case of Widespread Pelvic and Abdominal Dissemination of Uterine Leiomyosarcoma

doi:10.12280/gjfckx.20210520

Abstract

Abstract:

It is difficult to distinguish uterine leiomyoma from early leiomyosarcoma in terms of clinical manifestations and ancillary examinations. Due to the lack of tumor-free concept, the use of fibroid breakers without protective measures will increase the risk of intrapulmonary spread of leiomyosarcoma in the womb and results in a poor prognosis. The diagnosis and treatment of a case of abdominal distension after laparoscopic subtotal hysterectomy with a splitter in Gansu Provincial Maternity and Child-Care Hospital was retrospectively analyzed. It was considered that uterine leiomyosarcoma was widely spread in the pelvic and abdominal cavity, and the diagnosis and treatment of adjuvant chemotherapy after tumor cytoreduction was performed. And the relevant literature was reviewed, so as to fully understand the risk of laparoscopy myoma fragmentation without protective measures.

Key words: Leiomyosarcoma, Uterine neoplasms, Laparoscopy, Fibroid morcellator, Tumor spread

SUN Jian-hao, WU Zhen-zhen, MAO Bao-hong, WANG Fang, WANG Yue-yuan, ZHANG Ying, MA Fu-tang, LIU Qing. A Case of Widespread Pelvic and Abdominal Dissemination of Uterine Leiomyosarcoma[J]. Journal of International Obstetrics and Gynecology, 2022, 49(1): 49-52.

Figures/Tables 6

References 18

[1]	梁金晓, 林仲秋. 《FIGO 2018癌症报告》——子宫肉瘤诊治指南解读[J]. 中国实用妇科与产科杂志, 2018, 34(12):1366-1371. doi: 10.19538/j.fk2018120116. doi: 10.19538/j.fk2018120116
[2]	Parker WH. Indications for morcellation in gynecologic surgery[J]. Curr Opin Obstet Gynecol, 2018, 30(1):75-80. doi: 10.1097/GCO.0000000000000427. doi: 10.1097/GCO.0000000000000427
[3]	Holzmann C, Kuepker W, Rommel B, et al. Reasons to Reconsider Risk Associated With Power Morcellation of Uterine Fibroids[J]. In Vivo, 2020, 34(1):1-9. doi: 10.21873/invivo.11739. doi: 10.21873/invivo.11739 pmid: 31882457
[4]	Sizzi O, Manganaro L, Rossetti A, et al. Assessing the risk of laparoscopic morcellation of occult uterine sarcomas during hysterectomy and myomectomy: Literature review and the ISGE recommendations[J]. Eur J Obstet Gynecol Reprod Biol, 2018, 220:30-38. doi: 10.1016/j.ejogrb.2017.10.030. doi: 10.1016/j.ejogrb.2017.10.030
[5]	Brennan L, Milad MP, King LP. The Morcellation "Debate" and the FDA 510(k) Process-A Call for Further Reform[J]. Obstet Gynecol Surv, 2019, 74(12):679-692. doi: 10.1097/OGX.0000000000000733. doi: 10.1097/OGX.0000000000000733 pmid: 31881092
[6]	U.S. Food and Drug Administration. Laparoscopic Uterine Power Morcellation in Hysterectomy and Myomectomy: FDA Safety Communication[EB/OL]. [2014-8-10]. http://www.fda.gov/medicaldevices/safety/alertsandnotices/ucm393576.htm.
[7]	Zhang J, Li T, Zhang J, et al. Clinical Characteristics and Prognosis of Unexpected Uterine Sarcoma After Hysterectomy for Presumed Myoma With and Without Transvaginal Scalpel Morcellation[J]. Int J Gynecol Cancer, 2016, 26(3):456-463. doi: 10.1097/IGC.0000000000000638. doi: 10.1097/IGC.0000000000000638
[8]	余筱, 郝敏. 子宫肉瘤49例术前诊断及预后分析[J]. 中华临床医师杂志(电子版), 2015(13):2619-2622. doi: 10.3877/cma.j.issn.1674-0785.2015.13.037. doi: 10.3877/cma.j.issn.1674-0785.2015.13.037
[9]	Anupama R, Ahmad SZ, Kuriakose S, et al. Disseminated peritoneal leiomyosarcomas after laparoscopic "myomectomy" and morcellation[J]. J Minim Invasive Gynecol, 2011, 18(3):386-389. doi: 10.1016/j.jmig.2011.01.014. doi: 10.1016/j.jmig.2011.01.014
[10]	Della Badia C, Karini H. Endometrial stromal sarcoma diagnosed after uterine morcellation in laparoscopic supracervical hysterectomy[J]. J Minim Invasive Gynecol, 2010, 17(6):791-793. doi: 10.1016/j.jmig.2010.07.001. doi: 10.1016/j.jmig.2010.07.001
[11]	丁超, 张英丽, 朱笕青. 肌瘤粉碎机降低隐匿性子宫平滑肌肉瘤的无病生存期[J]. 中国现代医生, 2020, 58(29):93-97.
[12]	子宫肌瘤的诊治中国专家共识专家组. 子宫肌瘤的诊治中国专家共识[J]. 中华妇产科杂志, 2017, 52(12):793-800. doi: 10.3760/cma.j.issn.0529-567x.2017.12.001. doi: 10.3760/cma.j.issn.0529-567x.2017.12.001
[13]	U.S.Food and Drug Administration. UPDATE: The FDA recommends performing contained morcellation in women when laparoscopic power morcellation is appropriate[EB/OL]. [2020-02-25]. https://www.fda.gov/medical-devices/safety-communications/updatefda-recommends-performing-cont-ained-morcellation-women-when-laparoscopic-power-morcellation.
[14]	中国医师协会妇产科医师分会妇科肿瘤专业委员会(学组). 实施腹腔镜下子宫(肌瘤)分碎术的中国专家共识[J]. 中国实用妇科与产科杂志, 2020, 36(7):626-632. doi: 10.19538/j.fk2020070113. doi: 10.19538/j.fk2020070113
[15]	Halaska MJ, Haidopoulos D, Guyon F, et al. European Society of Gynecological Oncology Statement on Fibroid and Uterine Morcellation[J]. Int J Gynecol Cancer, 2017, 27(1):189-192. doi: 10.1097/IGC.0000000000000911. doi: 10.1097/IGC.0000000000000911
[16]	Shi X, Shi L, Zhang S. A comparative study on the short-term clinical efficacy of the modified laparoscopic uterine comminution technique and traditional methods[J]. Mol Clin Oncol, 2020, 12(3):237-243. doi: 10.3892/mco.2020.1982. doi: 10.3892/mco.2020.1982
[17]	Han A, Hong K, Kim M, et al. Unexpected uterine smooth muscle tumor of uncertain malignant potential and sarcoma: A single center cohort study in South Korea[J]. Taiwan J Obstet Gynecol, 2020, 59(2):275-281. doi: 10.1016/j.tjog.2020.01.017. doi: 10.1016/j.tjog.2020.01.017
[18]	刘红, 石宇, 张国楠, 等. 术后病理意外发现子宫肉瘤的临床病理分析及处理[J]. 肿瘤预防与治疗, 2020, 33(5):414-422. doi: 10.3969/j.issn.1674-0904.2020.05.007. doi: 10.3969/j.issn.1674-0904.2020.05.007